{
    "id": "5c6e4c9d-b85e-493f-9420-ab2fd0ff3723",
    "indications": "cholbam bile acid indicated : • treatment bile acid synthesis disorders due single enzyme defects ( seds ) . ( 1.1 ) • adjunctive treatment peroxisomal disorders ( pds ) including zellweger spectrum disorders patients exhibit manifestations liver disease , steatorrhea complications decreased fat-soluble vitamin absorption . ( 1.2 ) limitations : safety effectiveness cholbam extrahepatic manifestations bile acid synthesis disorders due seds pds including zellweger spectrum disorders established . ( 1.3 ) .",
    "contraindications": "• recommended 10 15 mg/kg daily two divided doses , pediatric patients adults . prescribing information weight-based dosing tables . ( 2.1 ) • recommended patients concomitant familial hypertriglyceridemia 11 17 mg/kg daily two divided doses adjusted based response . ( 2.1 ) • monitor ast , alt , ggt , alkaline phosphatase , bilirubin inr every month first 3 months , every 3 months next 9 months , every 6 months next three years annually thereafter . administer lowest dose effectively maintains liver function . ( 2.2 ) • discontinue cholbam liver function improve within 3 months starting treatment , complete biliary obstruction develops , persistent laboratory indicators worsening liver function cholestasis ; continue monitor liver function consider restarting lower dose parameters return baseline . ( 2.2 , 5.1 ) instructions : • take food . ( 2.3 ) • crush chew capsules . patients unable swallow capsules , capsules opened contents mixed drink/food ( 2.3 )",
    "warningsAndPrecautions": "50 mg capsules cholbam capsules available two-piece gelatin capsules swedish orange cap imprinted “ 50mg ” swedish orange body imprinted “ ask001 ” . capsules contain white off-white powder supplied bottles : •90 capsules ( ndc 79378-001-02 ) 250 mg capsules cholbam capsules available two-piece gelatin capsules white cap imprinted “ 250mg ” white body imprinted “ ask002 ” . capsules contain white off-white powder supplied bottles : •90 capsules ( ndc 79378-002-02 ) storage handling store 20°c–25○c ( 68°f–77○f ) , excursions permitted 15°c–30○c ( 59°f–86○f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "CHOLIC ACID",
            "code": "G1JO7801AE"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "organization": "Mirum Pharmaceuticals Inc.",
    "name": "CHOLBAM",
    "effectiveTime": "20250509",
    "indications_original": "CHOLBAM is a bile acid indicated for: • Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) • Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ).",
    "contraindications_original": "• The recommended dosage is 10 to 15 mg/kg once daily or in two divided doses, in pediatric patients and adults. See prescribing information for weight-based dosing tables. ( 2.1 ) • The recommended dosage in patients with concomitant familial hypertriglyceridemia is 11 to 17 mg/kg once daily or in two divided doses and is adjusted based on clinical response. ( 2.1 ) • Monitor AST, ALT, GGT, alkaline phosphatase, bilirubin and INR every month for the first 3 months, every 3 months for the next 9 months, every 6 months during the next three years and annually thereafter. Administer the lowest dose that effectively maintains liver function. ( 2.2 ) • Discontinue CHOLBAM if liver function does not improve within 3 months of starting treatment, if complete biliary obstruction develops, or if there are persistent clinical or laboratory indicators of worsening liver function or cholestasis; continue to monitor liver function and consider restarting at a lower dose when parameters return to baseline. ( 2.2 , 5.1 ) Administration Instructions: • Take with food. ( 2.3 ) • Do not crush or chew the capsules. For patients unable to swallow the capsules, the capsules can be opened and the contents mixed with drink/food ( 2.3 )",
    "warningsAndPrecautions_original": "50 mg Capsules\n                  \n                  CHOLBAM capsules are available as two-piece gelatin capsules with a Swedish orange cap imprinted with “50mg” and Swedish orange body imprinted with “ASK001”. The capsules contain a white or off-white powder and are supplied in bottles of: \n                  \n                     \n                        •90 capsules (NDC 79378-001-02)\n                  \n                  \n                     250 mg Capsules\n                  \n                  CHOLBAM capsules are available as two-piece gelatin capsules with a white cap imprinted with “250mg” and white body imprinted with “ASK002”. The capsules contain a white or off-white powder and are supplied in bottles of:\n                  \n                     \n                        •90 capsules (NDC 79378-002-02)\n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20°C–25○C (68°F–77○F), excursions permitted between 15°C–30○C (59°F–86○F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "None."
}